NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
Clinical Trials
169 trialsNCT03215030 2026-01-29
iinnovate-1
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT03590652 2025-10-21
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Terminated
NCT03287908 2025-10-08
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Amgen
Phase 1 Terminated
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
NCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04503668 2025-06-18
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center
Phase 3 Terminated
NCT05027594 2025-06-13
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
Nerviano Medical Sciences
Phase 1 Terminated
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04892264 2025-05-18
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Mayo Clinic
Phase 1 Terminated
NCT04570631 2025-05-16
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Terminated
NCT03576547 2025-05-08
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04892446 2025-05-02
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 2 Terminated
NCT00253318 2025-04-27
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
NCT04896658 2025-04-03
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT03871829 2025-03-30
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Janssen Research & Development, LLC
Phase 2 Terminated
NCT03457142 2025-03-04
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT04700176 2025-02-25
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT04150965 2025-02-14
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Multiple Myeloma Research Consortium
Phase 1/2 Terminated
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT05289492 2024-10-26
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
iTeos Therapeutics
Phase 1 Terminated
NCT02002598 2024-09-19
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
Phase 1/2 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT03488225 2024-07-16
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT02400242 2024-07-09
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Celgene
Phase 1 Terminated
NCT02863991 2024-07-03
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
Phase 1/2 Terminated
NCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated
NCT04956302 2024-06-06
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT04407442 2024-04-30
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
University of California, San Francisco
Phase 2 Terminated
NCT05641324 2024-02-12
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Anaveon AG
Phase 1 Terminated
NCT04912427 2024-02-09
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Washington University School of Medicine
Phase 1 Terminated
NCT04840615 2024-02-02
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated
NCT02188368 2023-11-03
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Oncotherapeutics
Phase 2 Terminated
NCT02294357 2023-11-01
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
Phase 2 Terminated
NCT04843579 2023-10-25
ClaSPd
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03201250 2023-09-08
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
University of Nebraska
Phase 1/2 Terminated
NCT02906332 2023-08-22
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Hackensack Meridian Health
Phase 2 Terminated
NCT04119336 2023-08-21
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Massachusetts General Hospital
Phase 2 Terminated
NCT04276090 2023-07-25
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
University of Kentucky
Phase NA Terminated
NCT02592707 2023-07-19
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Ipsen
Phase 1/2 Terminated
NCT00335140 2023-07-03
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT04156828 2023-06-29
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
Phase 1 Terminated
NCT04649060 2023-06-08
LIGHTHOUSE
Oncopeptides AB
Phase 3 Terminated